- Supply chain disruptions due to extreme weather events (particularly in Pakistan, China, Mexico, Spain, USA, and Italy).
- Emerging regulations on F-gases and PFAS substances.
- Potential introduction of carbon tax in various countries.
- Increasing competition from products with reduced climate impact.
Chiesi Farmaceutici SpA SB
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Chiesi Farmaceutici SpA SB disclosed greenhouse gas emissions of 949.6K t CO2e (Scope 3). By scope: Scope 1: 29.906 t CO2e; Scope 2: 12.254 t CO2e (location based), 591 t CO2e (market based); Scope 3: 949.6K t CO2e. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
949.6K t CO2e (Scope 3)
2023
Renewable Energy
99%
of total energy
Water Usage
299.89 ML (withdrawal), 98.75 ML (consumption)
2023
Energy Use
498.908 GJ
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 29.906 t CO2e |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 12.254 t CO2e (location based), 591 t CO2e (market based) |
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | 949.6K t CO2e |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 949.6K t CO2e (Scope 3) |
| 2021 | 43.7K tCO2e/year |
| 2020 | 815.115 tCO2e/year |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Achieved 99% renewable electricity consumption in 2023.
- Reduced energy intensity by 28% from 2019 baseline.
- Reduced Scope 1 CO2e emissions by 12% from 2019 baseline.
- Reduced Scope 2 (market-based) CO2e emissions by 96% from 2019 baseline.
- Reduced intensity of Scope 1 + 2 (market-based) CO2e emissions by 53% from 2019 baseline.
- Introduced new packaging for a key product, replacing polystyrene with FSC-certified paper.
- Achieved LEED Platinum certification for new headquarters and Warsaw office, LEED Gold for other buildings.
- Obtained Ecovadis Platinum medal with a score of 78/100.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Reduce Scope 1 and 2 GHG emissions by 90% by 2030.
- Reduce Scope 3 GHG emissions from use of sold products by 80% per unit by 2030.
- Complete clinical development for Carbon Minimal pMDI portfolio by 2025.
📅 Medium-term
- Achieve 100% renewable electricity by 2025.
🔭 Long-term
- Reduce absolute Scope 3 GHG emissions by 90% by 2035.
- Achieve Net Zero GHG emissions across the value chain by 2035.
🌱 ESG Focus Areas
Climate ChangeSustainable Development Goals (SDGs)Gender EqualityCommunity DevelopmentResponsible Business PracticesValue Chain SustainabilityGovernance